CAREFUSION CORPORATION UNDERWRITING AGREEMENT May 15, 2014Underwriting Agreement • May 16th, 2014 • CAREFUSION Corp • Surgical & medical instruments & apparatus • New York
CareFusion Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule II hereto (the “Underwriters”), acting severally and not jointly, the respective amounts set forth in Schedule II of $300 million aggregate principal amount of the Company’s 1.450% Notes due 2017, $400 million aggregate principal amount of the Company’s 3.875% Notes due 2024 and $300 million aggregate principal amount of the Company’s 4.875% Notes due 2044 (collectively, the “Securities”). Barclays Capital Inc., J.P. Morgan Securities LLC and Merrill Lynch, Pierce, Fenner & Smith Incorporated (collectively, the “Representatives”) have agreed to act as the representatives of the several Underwriters in connection with the offering and sale of the Securities.
